Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study
about
Treatment of gastric cancerMolecular-targeted first-line therapy for advanced gastric cancerNew advances in targeted gastric cancer treatmentAnticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesisExploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literatureClinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinomaCurrent and emerging therapies in unresectable and recurrent gastric cancerEmerging molecular classifications and therapeutic implications for gastric cancerPerioperative and Palliative Chemotherapy for Esophageal CancerFibroblast growth factor receptor signaling as therapeutic targets in gastric cancerAdvanced gastric cancer: Current treatment landscape and future perspectivesNovel targets in the treatment of advanced gastric cancer: a perspective reviewCurrent Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical ApplicationTargeted therapy for advanced gastric cancer: A review of current status and future prospectsNeo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectivesChanging strategies for target therapy in gastric cancerPersonalized medicine in gastric cancer: Where are we and where are we going?Advanced gastric cancer: What we know and what we still have to learnGastric cancer: The times they are a-changin'Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological featuresRamucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinomaState of the art management of metastatic gastroesophageal cancerMolecular Dimensions of Gastric Cancer: Translational and Clinical PerspectivesNeoadjuvant therapy for gastric cancer: current evidence and future directionsClinical utility of ramucirumab in advanced gastric cancerRamucirumab: A New Therapy for Advanced Gastric CancerEfficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsChemotherapy beyond second-line in advanced gastric cancerOptimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysisMolecular classification of gastric cancer: Towards a pathway-driven targeted therapyMultimodal treatment of gastric cancer in the west: Where are we going?Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision MedicineCritical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancersThe impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic reviewClinical practice guidelines for gastric cancer in Korea: an evidence-based approachNext-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneityAnti-vascular endothelial growth factor therapy in breast cancerTargeted therapy in gastric cancer: personalizing cancer treatment based on patient genomeTargeting receptor tyrosine kinases in gastric cancerGastric cancer review
P2860
Q24602875-BFB85576-2DF1-4D0E-ABE4-C7272404E7C1Q26471049-4246638D-688D-4507-A8C9-3CA96D428FD3Q26738548-4DD076FF-513E-40B1-B25B-374A68BF816BQ26740812-C5627875-0D9B-4C32-AFA0-7EA5C70273F9Q26741242-8255FC39-D171-4185-990B-9E64ADF8C420Q26741530-80A479A6-64B4-46F0-BDA6-4A6AB7A820A1Q26745453-CD358AC7-8358-4CA5-B798-3887E293EA76Q26745525-DEAC9807-547B-4896-9864-748F53C9A4B3Q26753865-2B808110-A392-4BFD-8F3A-D0B093C9D83CQ26764932-138616F9-2CEB-4A11-B70B-7D9A2BB26BAFQ26764934-E71C65C2-3616-43C8-97F6-0952449544ADQ26765208-B3EAF44C-54E0-4DA6-9563-8BB4ED2DC48AQ26765941-69A4F142-83F4-4A3A-9BDD-67B9709C60C2Q26774138-AE242A95-A0A7-4475-B3F1-BF7D0C7915D6Q26774283-F64D9C59-0F94-426C-A9BA-8AF381B69850Q26774513-4C6B10AC-B966-4CC8-AF94-3F8CE15E2FEAQ26774521-71501386-A90B-427E-8887-C7995B993FAEQ26774528-0EAFEAB8-4467-4653-BF83-EDF774090D59Q26776195-9C445589-9658-4EF5-B1E6-352BFA05F310Q26776198-B928444D-B129-484E-B661-5944BE9C6052Q26777690-05817F61-0E39-418A-A968-C537551BDD81Q26779217-907DC3DA-824D-419A-B283-DB6B3FB4B015Q26779725-814461A8-A80A-4CC5-B5CF-0036B2DE1292Q26781043-5EA79B26-5202-42FE-AAFA-F3E3F452120FQ26785665-6E019D6D-BA78-4298-8745-2CE9B9549152Q26785706-75F52AF9-F25D-438F-9413-F62885A685A4Q26786618-AD9F130F-C2EE-4668-9D04-1B8643968DCBQ26798288-704F9145-E602-48C8-A95D-3D96E4419F3AQ26798400-935C5E2E-E115-4133-89C4-AA785D0B60A0Q26798420-663B24E3-8666-4B6A-B59C-2F9E255AEDC8Q26799748-647542D7-F263-49CA-994D-8DC241601214Q26800355-663DF806-B62F-4C9C-BEF8-735C49433444Q26801289-ECD87194-AC3F-40B3-B4E6-46BE5769DEF0Q26824086-2002242C-E9F4-43F3-85CE-A6DACEBEA1F0Q26828506-7F081AE5-47FD-40FB-9EDA-DAB4918D3767Q26992272-E88E1574-6397-43FB-BDB1-6A6B781469D7Q26999473-068CAFA1-A5C2-4871-9D91-9B77984A643BQ27008274-498EF7D6-7B23-4734-BCD9-D800E8FA3852Q27013050-CFB4B39A-47AC-4CC1-A7A8-E237CDE43741Q27025793-7FC0B02A-1F3F-4309-9283-4D078AC90B9A
P2860
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Bevacizumab in combination wit ...... ebo-controlled phase III study
@ast
Bevacizumab in combination wit ...... ebo-controlled phase III study
@en
type
label
Bevacizumab in combination wit ...... ebo-controlled phase III study
@ast
Bevacizumab in combination wit ...... ebo-controlled phase III study
@en
prefLabel
Bevacizumab in combination wit ...... ebo-controlled phase III study
@ast
Bevacizumab in combination wit ...... ebo-controlled phase III study
@en
P2093
P921
P3181
P356
P1476
Bevacizumab in combination wit ...... ebo-controlled phase III study
@en
P2093
Akira Sawaki
Atsushi Ohtsu
Bernd Langer
Eric Van Cutsem
Ho Yeong Lim
Manish A Shah
Michal Starnawski
Sook Ryun Park
Yasuhide Yamada
P304
P3181
P356
10.1200/JCO.2011.36.2236
P407
P577
2011-08-15T00:00:00Z